Association of Gene Mutations, Drug Resistance, and Disease Progression in Lung Cancer Therapy

Abstract

Lung cancer is one of the most common causes of cancer deaths around the world and mutations in genes are largely responsible for the subsequent response to treatment and progression of the disease. In this study we examined the relationship between specific mutations, drug resistance and disease progression in patients with lung cancer who are receiving targeted therapy. A focus on clinically significant mutations (EGFR, KRAS and ALK) that affect treatment and prognosis. Data collection is quantitative correlational research design based on data from oncology departments, diagnostic laboratories. Statistical techniques: correlation, regression and logistic regression analysis are used to explore the relationship between gene mutations and resistance to treatment and progression rates. The aim of the study is to further the scientific understanding of molecular mechanisms associated with treatment failure and disease progression in the field of precision oncology. The results will help inform treatment approaches that are more effective, based on mutations.